Syros Pharmaceuticals (SYRS) was downgraded to a Hold Rating at TD Cowen
Syros Pharmaceuticals (SYRS – Research Report) received a Hold rating and price target from TD Cowen analyst Phil Nadeau yesterday. The ...
Syros Pharmaceuticals Shares Plummet Premarket After Study Failure
Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer.